Search details
1.
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Mol Cancer Ther
; 21(7): 1047-1059, 2022 07 05.
Article
in English
| MEDLINE | ID: mdl-35511740
2.
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Mol Cancer Ther
; 19(11): 2235-2244, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32967924
3.
Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator.
J Steroid Biochem Mol Biol
; 109(1-2): 129-37, 2008 Mar.
Article
in English
| MEDLINE | ID: mdl-18164613
4.
AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.
Neuropharmacology
; 58(2): 365-73, 2010 Feb.
Article
in English
| MEDLINE | ID: mdl-19835892
5.
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
J Pharmacol Exp Ther
; 317(2): 910-8, 2006 May.
Article
in English
| MEDLINE | ID: mdl-16469866
6.
Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
J Pharmacol Exp Ther
; 310(3): 943-51, 2004 Sep.
Article
in English
| MEDLINE | ID: mdl-15102927
Results
1 -
6
de 6
1
Next >
>>